PurpleDaisy Logo
PurpleDaisyResources
BiomarkersReference MatrixLab PanelsCalculatorsCompareGuidesBlog
Download on the App Store
BiomarkersReference MatrixLab PanelsCalculatorsCompareGuidesBlog

Biomarker Encyclopedia

500+ Items
Master Catalogs
  • All 500+ Biomarkers Directory
  • Longevity Reference MatrixPDF
Categories (500+ Markers)
  • Cardiovascular & Lipidology
  • Metabolic & Glycemic Control
  • Renal Physiology & Electrolytes
  • Hepatic & Biliary Function
  • Hematology & CBC
  • Iron Metabolism & Oxygen Transport
  • Endocrinology & Hormones
  • Micronutrients & Vitamins
  • Immunology & Longevity Clocks
Download Meridian on the App Store
Home/Biomarkers/Cardiovascular & Lipidology/Non-HDL-C
Cardiovascular & LipidologyAtherogenic Lipoprotein Burden

Non-HDL Cholesterol (Non-HDL-C)

Non-HDL cholesterol quantifies the total cholesterol mass carried within all atherogenic particles (LDL, VLDL, IDL, Lp(a)). It serves as a superior risk marker to LDL-C in hypertriglyceridemic states.

Standard Range< 130 mg/dL
Optimal Longevity< 90 mg/dL
Measurement Unitmg/dL
Organ SystemAtherogenic Lipoprotein Burden
Routine Panels:Calculated Lipid Metric (Total Cholesterol minus HDL)

Standard vs. Optimal Reference Rangesmg/dL

Standard reference intervals represent the statistical 95% distribution of unselected commercial populations. Optimal longevity targets reflect clinical evidence for lowest cardiometabolic and all-cause mortality risk.

Interactive Range Analyzer
Unit: mg/dL
mg/dL
Presets:
0 mg/dLOptimal Zone Target176 mg/dL
Optimal Longevity Zone(45 mg/dL)

Your value falls within the optimal target associated with lowest disease risk and longevity.

Standard Reference Interval

< 130 mg/dL

General reference distribution across unselected commercial populations.

Optimal Longevity Target

< 90 mg/dL

Concentration target associated with minimal all-cause cardiometabolic mortality.

Molecular Mechanism & Clinical Purpose

Calculated by subtracting HDL-C from Total Cholesterol. In metabolic syndrome and diabetes, triglyceride-rich remnant particles carry substantial cholesterol mass not captured by standard calculated LDL-C formulas.

Differential Diagnosis

Elevated Levels (Non-HDL-C High)

  • •Atherogenic dyslipidemia
  • •Metabolic syndrome
  • •Type 2 Diabetes
  • •Familial combined hyperlipidemia

Low Levels (Non-HDL-C Low)

  • •Low overall lipoprotein synthesis
  • •PCSK9 inhibitor therapy

Technical Reference & Deep Dive

Biochemistry & Enzymatic Pathways
At the cellular and molecular level, Non-HDL Cholesterol (Non-HDL-C) is central to lipoprotein particle assembly, apolipoprotein-receptor interactions, and subendothelial retention kinetics. Synthesis occurs primarily within hepatocytes and enterocytes, regulated by transcriptional co-activators (such as SREBP-2 and PPAR-alpha) and microsomal triglyceride transfer protein (MTP). Particle clearance is mediated through high-affinity endocytic receptors (including LDLR, LRP1, and scavenger receptors SR-B1). Circulating plasma half-life ranges from 2 to 4 days. Transcytosis across vascular endothelial cell monolayers occurs via scavenger receptor class B type 1 (SR-B1) and activin-like kinase 1 (ALK1), trapping particles within the subendothelial proteoglycan matrix where oxidative modification initiates foam cell formation.
Longevity Risk Architecture & Epidemiology
Lower non-HDL-C over the lifespan directly mitigates vascular intima-media thickening and preserves arterial compliance.
Pre-Analytical Caveats & Diagnostic Workup

Pre-Analytical Considerations:

Standard testing requires a 10 to 12 hour overnight fast to minimize postprandial chylomicron interference, although Non-HDL-C direct immunoassay is less sensitive to prandial state than calculated LDL-C. Avoid strenuous high-intensity exercise 24 hours prior to blood draw. Serum separator tubes (SST) or EDTA plasma should be centrifuged within 2 hours. High-dose biotin (>5 mg/day) supplementation may interfere with competitive streptavidin-biotin immunoassays, requiring a 48-hour washout period.

Reflexive Testing Protocol:

  • Advanced Lipoprotein Particle Quantification (NMR spectroscopy or ion mobility LDL-P)
  • Lipoprotein(a) [Lp(a)] baseline evaluation for genetic cardiovascular risk stratification
  • Coronary Artery Calcium (CAC) score via non-contrast cardiac CT to evaluate calcified plaque burden
  • High-sensitivity C-Reactive Protein (hs-CRP) to assess systemic vascular inflammatory tone
  • Carotid intima-media thickness (CIMT) duplex ultrasound to assess subclinical atherosclerosis
Clinical Citations & Primary Literature (1)
  • [1]Non-HDL Cholesterol and Long-Term Risk of Cardiovascular Disease - Lancet (2020). PMID: 31810609
Common Panels:Calculated Lipid Metric (Total Cholesterol minus HDL)
View All Panels

Associated Longevity Guides & Clinical Calculators

Medicine 3.0

Explore comprehensive evidence-based clinical protocols, testing costs, and algorithmic calculators that incorporate Non-HDL Cholesterol (Non-HDL-C) into overall healthspan optimization.

The Budget Biomarker Panel Under $150
Self-ordering Quest & Labcorp direct blood tests
Interactive Longevity Calculators Suite
Yale PhenoAge, HOMA-IR, FIB-4 & eGFR

Related Cardiovascular & Lipidology Biomarkers

Apolipoprotein B
ApoB · < 60 mg/dL (or < 50 mg/dL in high-risk phenotypes)
Low-Density Lipoprotein Cholesterol
LDL-C · < 70 mg/dL (or < 55 mg/dL in secondary prevention)
Serum Triglycerides
TG · < 80 mg/dL (Fasting)
PreviousTotal Serum Cholesterol (TC)Cardiovascular & LipidologyNextHigh-Sensitivity C-Reactive Protein (hs-CRP)Cardiovascular & Lipidology